Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
Ingevity Corp. (NGVT) reported third-quarter 2026 net sales of $305.1 million, versus $333.1 million a year earlier. Net income was $49.3 million, compared with $43.5 million, while income from continuing operations was $51.1 million versus $40.8 million. Total Segment EBITDA was $114.7 million, compared with $121.7 million.
For the nine months ended September 30, 2026, net income was $144.4 million, versus a net loss of $82.5 million a year earlier; operating cash flow was $83.4 million versus $234.1 million, including a $113.2 million litigation settlement payment. Ingevity completed the industrial specialties and crude tall oil refinery divestiture on January 1, 2026, receiving all-cash proceeds of $93.1 million, and sold its road markings product line on April 15, 2026, for all-cash proceeds of $63.2 million.
It recorded a $32.1 million non-cash impairment on Advanced Polymer Technologies long-lived assets. Ingevity repurchased 1,804,168 shares for $126.3 million, inclusive of excise tax, during the nine months, with $172.2 million remaining under the authorization at September 30, 2026.
Ingevity Corp (NGVT) reported third-quarter 2026 net sales of $305.1 million, down 8% year over year, primarily reflecting the April 15, 2026, sale of its Road Markings product line; excluding Road Markings, sales increased 2%. Net income from continuing operations was $51.1 million, versus $40.8 million a year earlier, and diluted EPS was $1.46 versus $1.10. Adjusted earnings from continuing operations were $56.7 million, or $1.63 per adjusted diluted share. Adjusted EBITDA from continuing operations was $108.0 million, down $2.4 million, while its margin expanded 230 basis points to 35.4%.
Operating cash flow was $99.2 million, down $30.5 million, and free cash flow was $85.5 million, down $32.3 million. Full-year 2026 outlook is $385 million to $395 million adjusted EBITDA, approximately $1.1 billion net sales, $5.25 to $5.45 diluted adjusted EPS, and $220 million to $230 million free cash flow, excluding the second-quarter $113.2 million litigation settlement payment. The company said an agreement announcement for the Advanced Polymer Technologies sale may extend into early 2027.
Ingevity Corp director Francis David Segal received 335 vested deferred stock units (DSUs) on October 1, 2026, in lieu of quarterly director fees, following his election to receive DSUs instead of those fees. The transaction lists $71.09 per share, and Segal’s reported direct position following the transaction was 8,947 shares.
Ingevity Corp director J. Kevin Willis received 405 vested deferred stock units on October 1, 2026, reported at $71.09 per share. The units were granted in lieu of quarterly director fees and will settle into an equal number of common shares upon termination of board service. His reported post-transaction position was 11,883 shares.
Ingevity Corp (NGVT) reported that President & CEO David H. Li sold company common stock in three open-market transactions under a Rule 10b5-1 trading plan. On August 14, 2026 he sold 5,000 shares at a weighted average price of $75.73, with individual trades between $74.82 and $76.53. On August 17, 2026 he sold another 5,000 shares at a weighted average price of $75.83, with prices between $75.50 and $76.25. On August 18, 2026 he sold 92 shares at a weighted average price of $74.71, with trades between $74.39 and $74.96. In total, the filing reports sales of 10,092 shares of NGVT common stock held directly by Li.
Ingevity Corp President & CEO David H. Li reported open-market sales of company common stock under a Rule 10b5-1 trading plan. He sold 5,000 shares on August 12, 2026 at a weighted average price of $76.62 and 5,000 shares on August 13, 2026 at a weighted average price of $75.73, each executed through multiple trades within disclosed price ranges.
Ingevity Corp (NGVT) director and officer David H. Li reported a proposed sale of 20,092 common shares, with an aggregate market value of $1,562,956.68 and an approximate sale date of August 12, 2026. The shares were acquired from the issuer as restricted stock units on April 7, 2026. May 13, 2026 is listed as the date of plan adoption or giving of instruction if relying on Rule 10b5-1.
Ingevity Corp officer Phillip John Platt, SVP and Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-10, 1,698 shares were withheld by the company at $77.04 per share to satisfy tax withholding obligations related to 2024 restricted stock units that vested. Following this tax-withholding disposition, Platt’s directly held common stock position is 26,641 shares.
Ingevity Corp executive Ryan C. Fisher, SVP, General Counsel & Secretary, reported selling a total of 2,709 shares of common stock on August 3, 2026. The sales occurred in two non-derivative transactions classified as sales in open market or private transactions at $73.7600 and $73.6700 per share. The Rule 10b5-1 trading plan checkbox was not checked for these trades.
Ingevity Corp. officer Ryan C Fisher reported a planned sale of 2,709 shares of common stock, with an aggregate market value of $199,703.80 and an approximate sale date of August 3, 2026.
The securities information lists restricted stock acquired from the issuer on February 18, 2021. Remarks state the securities to be sold were acquired upon vesting from February 18, 2021, through July 5, 2026.